Course Description:

Participants will be introduced to major clinical steps and considerations in the new drug development process. Starting with the selection of medically promising molecules, through the execution of major I-IV phases of clinical trials, and ending in clinical profiling for marketing.

The course will address:

  • Standard procedures;
  • New strategies implemented in clinical trials;
  • Selection of clinical investigators, consultants and opinion leaders;
  • Interactions with regulatory agencies in various countries;
  • Impact of regulations on the programs; as well as other common challenges.

Participants will learn about similarities and differences in clinical strategies for standard vs unique molecules, for domestic vs global programs, and for large pharma projects vs small biotech companies.

Learning Objectives:

  • To understand the role of medical input in the selection of potentially therapeutic molecules and their subsequent clinical profiling.
  • To understand and be able to design the most appropriate strategy for a clinical program, including all clinical developmental phases, from IND to NDA/PLA.
  • To understand basic trial methodologies, study execution, monitoring and evaluation processes.
  • To understand the selection of the investigators and consultants in various countries; the criteria for study placement and their cost, as well as the concept of “go no go” clinical decision for the molecule.
  • To become familiar with common challenges and key issues effecting trial designs and their execution in different countries and difficult investigators.
  • To understand how to work with multifunctional and often multicultural teams.
  • To discuss the clinical part of FDA and ICH guidelines and their impact on clinical programs.

Seminar Fee Includes:

AM-PM Tea/Coffee
Seminar Material
USB with seminar presentation
Hard copy of presentation
Attendance Certificate
$100 Gift Cert for next seminar

Who will Benefit:

  • Junior or new staff of clinical pharmacology and clinical research departments.
  • Pre-clinical, business, legal and marketing professionals who wish to become familiar with the clinical drug development process and the interpretation of clinical data.
  • Investment or licensing community members who are interested in clinical programs, particularly in the process of planning, costs, timing and issues of clinical evolutions and/or profiling of new molecule.
  • Clinical research associates, project managers, research scientists, medical writers, clinical statisticians, junior regulatory personnel, licensing and acquisition staff.
  • Any college graduates who are contemplating careers in clinical research involving the bio-pharma industry.

Course Outline:

Day 1 (8:30 AM – 4:30 PM) Day 2 (8:30 AM – 5:00 PM)
  • 8:30 – 9:00 AM: Registration
  • 9:00 AM: Session Start Time

Morning Session A, 9:00 AM - 12:30 PM

Clinical considerations during preparation and conduct of first clinical trials in humans. Major goals are safety, early activity, and dose finding.

  • Challenges while deciding how and when to start a clinical program.
  • Patients or volunteers?
  • Define primary, disease dependent goals: safety only, or early efficacy, or “proof of concept”, or just PK.
  • Predictability of animal safety and activity to man. Problems with species specificity.
  • Clinically desirable formulations and their challenges.
  • Who decides which molecule goes to clinical Phase I testing. Differences between big pharma and small biotech/startups.
  • Financing issues.
  • Trial site selection and decisions regarding number and type of sites.
  • The targeted profile of a potential drug. Anticipated diseases /symptoms. Is market big or small for specialized diseases /orphan indications.
  • Potential clinical drug/drug interactions.
  • Impact of international/global vs. domestic strategy.
  • Considerations for acquisition and early licensing.
  • Q & A, open discussion forum.

Afternoon Session B, 1:00 PM - 4:30 PM

Phases I and/or I/II and II A or B. Early activity and efficacy. Early safety profile.

  • Are we searching primarily for early activity or already efficacy.
  • Investigator vs company sponsored IND.
  • Preliminary safety considerations. Evaluation and decision regarding acceptability of early side effects.
  • How to accrue/encourage participation of volunteers and/or patients.
  • Clear activity targets or “broad net”.
  • Exploration of one or more clinical indications, cost vs benefit.
  • Typical trial designs vs new approaches.
  • How do we define and explore potentially “effective vs active” doses.
  • Importance of pharmacokinetics in deciding the best dose ranges and regimens.
  • Collaborations with regulatory agencies.
  • Study monitoring.
  • Formulation changes and their impact on clinical trials.
  • Major “go no go” decisions.
  • “End of Phase II” meeting with the FDA and other agencies.
  • Strong suggestion of efficacy in Phase II. The next steps…
  • Q&A, open discussion forum.

Morning Session C, 8:30 AM - 12:30 PM

Providing definitive evidence of efficacy and safety.

  • Selecting most promising medical indications from the results of Phase II.
  • Marketing input into the targeted profile of a potential drug.
  • Agreements with regulatory agencies regarding definitive clinical trials: designs, dose selection, primary endpoints, statistical considerations.
  • Dependence of clinical trial design on disease under study, compassionate follow up programs.
  • How many independent trials are needed.
  • Challenges in the execution of a very large clinical program in a timely and efficient manner. Number and selection of multiple centers. Choice of domestic vs international sites,
  • Basis of investigator selection and importance of multi-center investigator meetings to secure consistency in the program and the pool-ability of results.
  • Impact of differences in local/national medical practices, diagnoses, and protocol compliance.
  • Safety evaluation in the conduct and interpretation of clinical trial conduct and results.
  • Importance of proper monitoring and monitor selection, CRO, and MRO.
  • Implementation of GCP (FDA versus ICH), detecting and dealing with investigator fraud or lack of adherence to the protocol.
  • Challenge of getting proper rate-of-patients-accruals. Methods to increase efficient enrollment and cost.
  • Strategies on dealing with two good, international pivotal trials where one ends up with strongly positive results whilst the other strongly negative.
  • Crucial interactions. Individual, small, or big multi-center meetings with investigators, monitoring consultants, regulatory agencies and opinion leaders.
  • Risk versus benefit consideration.
  • Q&A, open discussion forum.

Afternoon Session D, 1:00 PM to 5:00 PM

Final regulatory submissions. Secondary indications. Marketing support. Special issues.

  • NDA/PLA/Foreign regulatory submissions. Strategies regarding type, timing, electronic vs. old “paper standard”.
  • Advisory Committee clinical presentations.
  • Post approval safety programs.
  • Post approval clinical commitments.
  • Secondary/extended clinical indications. Academia and/or industry.
  • Approved clinical claims vs physician’s decisions on choice of treatment and use of the drug.
  • Safety problems showing up in Phase IV trials or post marketing phases. Late or rare toxicities.
  • Medical aspect of drug pricing issues.
  • Why the cost of clinical R&D —with the extending scope, duration and number of all trials— is rising. Its impact on clinical programs.
  • Q&A, open discussion forum.

Meet Your Instructor

Zofia Dziewanowska MD, PhD
Pharmaceutical Executive /Clinical Research & Regulatory

For over 30 years, Zofia E Dziewanowska MD, PhD, has been in charge of new drug development, including all Phases(I to IV, domestic and international) for big pharma like Merck and Hoffman la Roche, and smaller biotech start-ups like Genta and Ligand. Early in her career, she personally designed and conducted multiple clinical trials. Subsequently, she became the senior Clinical R&D Executive responsible for medical strategies, execution and management of programs which spanned multiple therapeutic areas. Dr. Dziewanowska submitted many successful NDAs. She has also participated in the selection of molecules for clinical development, including their profiling and post approval programs. She presented to regulatory agencies in US and Europe. Her academic affiliations included medical schools and institutes in the US and Europe. She organized numerous professional meetings and educational programs. Presently, she is a senior consultant to the biopharmaceutical industry as a founder and medical director of New Drug Associates.

Register Now

Online using Credit card

Get the Invitation
Pre-Register yourself and get the official Invite when venue and dates are announced for this seminar.
Call here to register +1-888-717-2436 or email at [email protected]

Other Registration Option

By order form / PO#

Payment Mode

By Check -
Pay your check to (payee name) “MetricStream Inc” our parent company and Mail the check to:

ComplianceOnline (MetricStream, Inc),
6201 America Center Drive Suite 240
San Jose, CA 95002

By Wire -

Register / Pay by Wire Transfer

Please contact us at +1-888-717-2436 to get details of wire transfer option.

Terms & Conditions to Register for the Seminar/Conference/Event

Your registration for the seminar is subject to following terms and conditions. If you need any clarification before registering for this seminar please call us @ +1-888-717-2436 or email us @ [email protected]

Payment is required 2 days before the date of the conference. We accept American Express, Visa and MasterCard. Make checks payable to MetricStream Inc. (our parent company).

Cancellations and substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 10 calendar days prior to the start date of the event will receive a refund — less a $200 administration fee. No cancellations will be accepted — nor refunds issued — within 10 calendar days before the start date of the event.

On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($200) will be transferred to any future ComplianceOnline event and a credit note will be issued.

Substitutions may be made at any time. No-shows will be charged the full amount.

We discourage onsite registrations, however if you wish to register onsite, payment to happen through credit card immediately or check to be submitted onsite. Conference material will be given on the spot if it is available after distributing to other attendees. In case it is not available, we will send the material after the conference is over.

In the event ComplianceOnline cancels the seminar, ComplianceOnline is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.

Attendance confirmation and documents to carry to the seminar venue:
After we receive the payment from the registered attendee, an electronic event pass will be sent to the email address associated with the registrant 5 working days before the seminar date. Please bring the pass to the venue of the event.

Conference photograph / video:
By registering and attending ComplianceOnline conference, you agree to have your photographs or videos taken at the conference venue and you do not have any objections to ComplianceOnline using these photos and videos for marketing, archiving or any other conference related activities. You agree to release ComplianceOnline from any kind of claims arising out of copyright or privacy violations.

Media Partners


Media Partner Benefits
  • Logo and company data on the event website.
  • Logo on the conference material distributed during the conference.
  • Media partner’s brochure distributed along with conference material.
  • Logo on all the mailings before and after the event.
  • 10% discount to media partner's subscribers.

Media Partner To Do
  • Banner (min 728x90 or 468x60) on the media partner website.
  • Insertion of the event in the event calendar, both printed and/or online.
  • Announcement article of the conference on the magazine and/or website.
  • Dedicated email blast to media partner’s subscribers.
  • Article on the magazine and/or website after the conference.

Local Attractions

The Philadelphia Museum of Art sits majestically on a rise at the end of the Benjamin Franklin Parkway. The vast collections of this temple of art make it the third-largest art museum in the country, and an absolute must-see on the city's cultural circuit.

Among its impressive holdings in Renaissance, American, Impressionist and Modern art, some standouts include a great Rogier van der Weyden altarpiece, a large Bathers by Cezanne, a room devoted to Philadelphia's own Thomas Eakins, and Marcel Duchamp's notorious mixed-media Bride Stripped Bare by her Bachelors (The Large Glass), exactly as the dada master installed it.

With more than 3,600 acres of rolling hills and well-worn trails, Valley Forge is now a magnet for runners, bicyclists and picnickers as well as history buffs.

The vast expanse of open space links the Schuylkill River Trail to the Horse Shoe Trail, turning the park into a major hub in a 75-mile system linking Philadelphia to the Appalachian Trail.

The Liberty Bell has a new home, and it is as powerful and dramatic as the Bell itself. Throughout the expansive, light-filled Center, larger-than-life historic documents and graphic images explore the facts and the myths surrounding the Bell.

The 160,000-square-foot National Constitution Center explores and explains this amazing document through high-tech exhibits, artifacts, and interactive displays. The Kimmel Theater, a 350-seat star-shaped theater, features “Freedom Rising,” a multimedia production combining film, a live actor and video projection on a 360° screen to tell the stirring story of “We the people.”

An innovator in designing hands-on exhibits before “interactive” became a buzzword, The Franklin Institute is as clever as its namesake. Its eminently touchable attractions explore science in disciplines ranging from sports to space.

Highlights include The Sports Challenge, which uses virtual-reality technology to illustrate the physics of sports; The Train Factory's climb-aboard steam engine; Space Command's simulated earth-orbit research station; a fully equipped weather station; and exhibits on electricity.

The Barnes Foundation was created in 1922, a school originating with Barnes’ educational experimentation in his Argyrol (pharmaceutical) factory. Barnes and The Foundation’s first director of education, John Dewey, were interested in fostering cognitive development through new approaches to education, and in heightening critical-thinking and problem-solving skills through the study of art. Barnes, like Dewey, was actively engaged in development of an intellectual framework and educational philosophies and practices with many of the best artists and thinkers of his day.

One of Philadelphia’s most famous pieces of public art is a bigger-than-life boxer… literally. Originally created for Rocky III, the sculpture is now a real-life monument to a celluloid hero. The fictional Rocky Balboa of Sylvester Stallone’s Rocky movies was immortalized in bronze in 1980. After filming for the movie completed, Stallone donated the statue to the City of Philadelphia.

Franklin Square, one of Philadelphia’s five original public squares laid out by William Penn in his original plan for the city, has undergone a dramatic renovation. The park now boasts several family-friendly attractions, including a miniature golf course, classic carousel, burger joint, storytelling bench, picnic area and more.

We need below information to serve you better



6201 America Center Drive Suite 240, San Jose, CA 95002, USA

Follow Us

facebook twitter linkedin youtube


Copyright © 2023 MetricStream
Our Policies: Terms of use | Privacy

PAYMENT METHOD: 100% Secure Transaction

payment method